TRIL Trillium Therapeutics Inc

EDISON EQUITY RESEARCH: TRILLIUM THERAPEUTICS - US$55M FINANCING EXTENDS RUNWAY AND FLEXIBILITY


Trillium raised US$55.2m (gross) through an offering of 1.751m common shares and 1.078m convertible preferred shares, at US$19.50 per share. We believe Trillium can fund lead asset SIRPaFc through Phase II trials and it will expand preclinical SIRPaFc work in cancers beyond acute myeloid leukemia (AML). Data presented at AACR 2015 confirm that SIRPaFc does not bind CD47 on human red blood cells (hRBCs), aiding its safety profile.

Trillium Therapeutics is a Canadian pharmaceutical company developing cancer therapeutics targeting immune-regulatory pathways that tumour cells exploit to evade the host immune system. Lead candidate SIRPaFc targets CD47 and is planned to start dosing in a Phase I study in AML in Q415.

To view our full report, please click here

Click here to view all of Edison Investment Research’s published reports